Novo Nordisk's Ryzodeg misses superiority endpoint in Phase III
This article was originally published in Scrip
Executive Summary
Novo Nordisk's Ryzodeg, sister compound to Tresiba (insulin degludec), has failed to meet its primary endpoint in a Phase IIIb trial.